drugset / Trial / NCT03784261
Usefulness of Non TNF Usage in RA Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Sarilumab treatment for 12 months 2. Tocilizmab treatment for 12 months 3. Abatacept treatment for 12 months
Timeline
- Start
- 2018-12-17
- Primary completion
- 2022-12-16
- Completion
- 2024-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abatacept | Other / unclassified | — | Subcutaneous |
| Comparator | Salirumab | Unknown | — | Subcutaneous |
| Comparator | Tocilizmab | Unknown | — | Subcutaneous |